Search Results
Your search for ,New matches 16922 pages
Showing 101 - 150A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
A Paradigm Shift in Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588). Globally, surgical standards vary on the...
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
The U.S. Food and Drug Administration (FDA) has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
New European Project Cluster EARLYSCAN Launched to Advance Early Detection of Heritable Cancers
A new European collaboration cluster, EARLYSCAN (Early Screening & Hereditary Cancer Awareness Network), has been launched to strengthen prevention and early detection strategies for heritable cancers. The cluster brings together three Horizon Europe–funded projects: SHIELD, DISARM, and...
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology. The study is a...
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%. The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (ER)-positive, HER2-negative stage I to III early breast cancer, marking the first phase III trial...
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews....
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25%
A team of researchers and physicians found that utilizing ultrasound-guided diffuse optical tomography (DOT) technology may reduce unnecessary breast biopsy rates by nearly 25%. Using this new method first—rather than starting with a biopsy—may help to determine if additional diagnoses are needed...
Researchers Advance Understanding of Female Sexual Anatomy to Improve Pelvic Cancer Radiotherapy
A recent, innovative study provides radiation oncologists with practical guidance to identify and protect female sexual organs during pelvic cancer treatment. Published by Greenwald et al in Practical Radiation Oncology, the report’s authors address a long-standing gap in cancer care by bringing...
CRI Launches Open Database for Immunotherapy Cancer Research
The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The...
Cancer Workforce Challenges Undermine Patient Care and Jeopardize Momentum in Research, Report Finds
The U.S. cancer workforce faces critical challenges that may affect Americans' access to lifesaving cancer care and delay progress in cancer research. A new report from the President's Cancer Panel, Ensuring a Strong Future for America's Cancer Workforce, underscores these key issues—including...
Colorectal Cancer: How Does Lifetime Alcohol Consumption Affect Risk?
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The...
Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma
In a phase II study reported in The Lancet Oncology, Monga et al found that dual targeting of vascular endothelial growth factor (VEGF) and mesenchymal epithelial transition factor receptor (MET) pathways with cabozantinib and temozolomide was of benefit in patients with unresectable or metastatic...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years old. Born in...
New Report Shows Colorectal Cancer Is Top Cause of Cancer Mortality in Those Under 50
A new study by American Cancer Society (ACS) researchers shows that overall cancer mortality in people younger than age 50 in the United States has decreased by 44%, from 25.5 per 100,000 people in 1990 to 14.2 in 2023. The progress is due to declines in mortality for four of the five leading...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Novel HER2-Targeted Bispecific Improves Outcomes in Patients With Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO,as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect upon the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George J....
New ASCO Guideline Addresses Management of Cancer During Pregnancy, From Diagnosis Through Survivorship
A new ASCO guideline provides recommendations on managing cancer during pregnancy, addressing a range of topics from the selection and timing of diagnostic testing and therapeutic interventions to delivery planning and ethical and legal considerations.1 The guideline aims to inform evidence-based...
Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
ASCO, in collaboration with Ontario Health (Cancer Care Ontario), has published an update to their previous guideline on the treatment of multiple myeloma.1 This new guideline—which has been selected as an ASCO Living Guideline—reflects dramatic changes that have helped improve the management of...
Case 3: Metastatic HR-Positive/HER2-Negative Breast Cancer With PTEN Loss and Emergent ESR1 Mutation
This is Part 3 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Dual Antigen Targeting of Drug-Resistant Extramedullary Myeloma
In a phase II trial (RedirecTT-1) reported in The New England Journal of Medicine, Kumar et al found that the combination of talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) produced high response rates in patients with...
Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation
In 2018, the federal government expanded the coverage duration of short-term limited-duration (STLD) health plans from 3 months to less than 12 months, with the option to renew for a total duration of up to 36 months. Some states imposed more stringent regulations than those federally imposed or...
Investigational Vaccine Could Prevent Cancer Development in Lynch Syndrome Carriers
An investigational cancer vaccine, NOUS-209, has shown potential for intercepting precancerous and cancerous cells before the disease can develop in individuals with Lynch syndrome, thereby showing the potential to prevent cancer from developing in these high-risk individuals, according to findings ...
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
The U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have collaborated with the European Medicines Agency (EMA) to develop a set of 10 guiding principles for good uses of artificial intelligence (AI) in...
Intensity-Modulated Proton vs Photon Radiotherapy in Oropharyngeal Cancer
In a prespecified interim analysis of a phase III trial (University of Texas MD Anderson Cancer Center Clinical Trial Consortium trial) reported in The Lancet, Frank et al found that intensity-modulated proton therapy (IMPT) was noninferior to standard intensity-modulated photon radiation therapy...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
Excluding skin cancers, breast cancer is the most commonly diagnosed cancer among women in the United States, accounting for about 30% of all new female cancers each year. In 2026, the American Cancer Society estimates that 322,000 new cases of invasive breast cancer and about 61,000 new cases of...
Can a Genetic Variant Affect the Efficacy of Abiraterone?
Data from a major clinical trial from the Alliance for Clinical Trials in Oncology have uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormonal treatment for advanced prostate cancer. Published by Norton et al in Clinical and Translational...
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Patients with unilateral breast cancer who underwent quantitative counseling with a personalized tool incorporating genetic testing results were better informed of their contralateral breast cancer risk compared with those who received standard counseling, according to results from the GET FACTS...
Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors
A virtual screening campaign using machine learning identified molecules with potential for development as novel CDK9 inhibitors for the treatment of cancer, according to early research findings published in Biomolecules. Integration of artificial intelligence (AI) into the drug discovery phase...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
ACS Report Shows 5-Year Survival for All Cancers Combined Has Reached 70%
New data published by Siegel et al in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed...
Multiple Myeloma: Sex Differences in Etiology and Clinical Presentation
Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Ong et al in the journal Cancer provides insights that may help to explain this disparity. To investigate the sex difference in...
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
In a phase III trial (GORTEC 2018-01, NIVOPOST-OP) reported in The Lancet, Bourhis et al found that the addition of adjuvant nivolumab to cisplatin and radiotherapy improved disease-free survival in patients with high-risk, resected, locally advanced squamous cell carcinoma of the head and neck...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
